- Home
- SWZ vs NRXP Comparison
SWZ vs NRXP Comparison
Compare SWZ & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWZ | NRXP |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 99.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SWZ | NRXP |
|---|---|---|
| Price | $5.97 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 76.1K | ★ 975.5K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | N/A | $1,591.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.84 | $1.65 |
| 52 Week High | $6.43 | $3.84 |
Technical Indicators
Market Signals| Indicator | SWZ | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 61.28 |
| Support Level | $5.90 | $2.78 |
| Resistance Level | $6.11 | $3.33 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 23.04 | 62.50 |
Price Performance
Historical ComparisonAbout SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. It actively manages investment solutions spanning public and private markets, wealth management, and Solutions.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.